QRXPharma writes off
Thursday, 21 August, 2008
QRxPharma (ASX: QRX) has had to write off $18 million in impairment charges this financial year, resulting in a $36 million deficit in the Brisbane-based company's bottom line.
The company accrued $18.1 million in non-cash impairment charges relating to intellectual property licensed from the University of Alabama.
Share based payment charges also accounted for $3.5 million of the deficit.
The remainder of the deficit is in line with QRxPharma's expectations, and has gone towards commercialising the company's Q8004IR dual-opioid oral analgesic, the company said.
The product is expected to be launched in 2010.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
